Healthcare - Drug Manufacturers - General - NASDAQ - FR
$ 47.97
0.314 %
$ 126 B
Market Cap
25.12
P/E
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema.[ Read More ]
The intrinsic value of one SNY stock under the base case scenario is HIDDEN Compared to the current market price of 48 USD, Sanofi is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart SNY
FINANCIALS
46 B
REVENUE
7.88 B
OPERATING INCOME
5.4 B
NET INCOME
10.3 B
OPERATING CASH FLOW
-6.2 B
INVESTING CASH FLOW
-8.05 B
FINANCING CASH FLOW
14.2 B
REVENUE
3.64 B
OPERATING INCOME
1.11 B
NET INCOME
0
OPERATING CASH FLOW
-3.41 B
INVESTING CASH FLOW
89 M
FINANCING CASH FLOW
Balance Sheet Decomposition
Sanofi
| Current Assets | 30.7 B |
| Cash & Short-Term Investments | 8.71 B |
| Receivables | 8.43 B |
| Other Current Assets | 13.5 B |
| Non-Current Assets | 95.8 B |
| Long-Term Investments | 3.26 B |
| PP&E | 11.8 B |
| Other Non-Current Assets | 80.7 B |
| Current Liabilities | 24.2 B |
| Accounts Payable | 7.33 B |
| Short-Term Debt | 2.32 B |
| Other Current Liabilities | 14.5 B |
| Non-Current Liabilities | 27.9 B |
| Long-Term Debt | 16.1 B |
| Other Non-Current Liabilities | 11.8 B |
EFFICIENCY
Earnings Waterfall
Sanofi
| Revenue | 46 B |
| Cost Of Revenue | 14.2 B |
| Gross Profit | 31.8 B |
| Operating Expenses | 23.9 B |
| Operating Income | 7.88 B |
| Other Expenses | 2.48 B |
| Net Income | 5.4 B |
RATIOS
69.12%
GROSS MARGIN
17.11%
OPERATING MARGIN
11.73%
NET MARGIN
7.29%
ROE
4.27%
ROA
6.76%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Sanofi
| Net Income | 5.4 B |
| Depreciation & Amortization | 4.79 B |
| Capital Expenditures | -3.25 B |
| Stock-Based Compensation | 0 |
| Change in Working Capital | 764 M |
| Others | 1.87 B |
| Free Cash Flow | 7 B |
Wall Street Analysts Price Targets
Sanofi
Wall Street analysts predict an average 1-year price target for SNY of $59.7 , with forecasts ranging from a low of $55 to a high of $64 .
SNY Lowest Price Target
Wall Street Target
55 USD
14.65%
SNY Average Price Target
Wall Street Target
59.7 USD
24.38%
SNY Highest Price Target
Wall Street Target
64 USD
33.42%
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
1.48 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Sanofi
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|
7. News
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.
benzinga.com
- 1 day ago
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistamines FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade Paris and Tarrytown, NY, November 15, 2024. The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment.
globenewswire.com
- 2 days ago
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma
Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination with VRd significantly improved progression-free survival, compared to standard-of-care VRd alone If approved, Sarclisa would be the first anti-CD38 therapy in the EU available for use in combination with VRd for adult patients with transplant-ineligible NDMM Paris, November 14, 2024. The European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT).
globenewswire.com
- 2 days ago
Healx announces agreement with Sanofi to seek new rare disease indications for compound using AI drug discovery platform
CAMBRIDGE, England--(BUSINESS WIRE)--Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease indications using Healnet, Healx's AI-driven drug discovery platform. Under the agreement, Sanofi will provide data related to a late stage discontinued asset that is being considered for out-licensing. Financial terms of the partnership are not disclosed. “Today, only 5% of rare diseases have an approved t.
businesswire.com
- 4 days ago
Sanofi: Diverse Drug Portfolio And Future Pipeline, 4% Dividend Yield Looks Attractive
Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse drug portfolio and a robust pipeline of future drugs to market, this big pharma brand will play a major role in treatments in the next decades to come. The stock currently offers a 4% dividend yield, while trading below its moving average and with a mixed valuation picture vs key peers.
seekingalpha.com
- 4 days ago
The Accumulus Platform Powers Sanofi's Submissions to Multiple Regulators Around the World
BURLINGAME, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Accumulus Synergy, Inc. (“Accumulus”), is revolutionizing the scalability of reliance pathways, enabling a recent submission from Sanofi to multiple national regulatory authorities (NRAs) around the globe. As industry leaders are set to leverage the Accumulus platform for upcoming projects, its ability to handle concurrent submissions across multiple jurisdictions is proving to be a game-changer.
globenewswire.com
- 1 week ago
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Approval based on phase 3 data showing significantly more children aged one to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one year Dupixent is the first-ever medicine in the EU indicated to treat these young patients, who persistently struggle to eat at a critical stage in life where growth is crucial Paris and Tarrytown, NY, November 6, 2024. The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age.
globenewswire.com
- 1 week ago
SandboxAQ CEO on the firm's partnership with Sanofi
Jack Hidary, CEO of SandboxAQ, says the firm's partnership with Sanofi aims to drive biomarker discovery in clinical development.
youtube.com
- 1 week ago
Resalis Therapeutics Gains Strategic Equity Investment from Sanofi
TORINO, Italy--(BUSINESS WIRE)--Resalis Therapeutics announced today a strategic equity investment from Sanofi. The company intends to use the proceeds to accelerate the development of its lead investigational candidate, RES-010, through a Phase 2 proof-of-concept clinical trial. RES-010 represents a first-in-class antisense oligonucleotide targeting miR-22, a non-coding RNA that plays a pivotal role in the molecular pathways underlying obesity. This innovative approach positions Resalis to pot.
businesswire.com
- 2 weeks ago
Why Sanofi Stock Flew Higher on Friday
No investor can ignore a crushing bottom-line beat and raised profitability guidance.
fool.com
- 3 weeks ago
Sanofi (SNY) Q3 2024 Earnings Call Transcript
Sanofi (NASDAQ:SNY ) Q3 2024 Earnings Conference Call October 25, 2024 8:00 AM ET Company Participants Thomas Kudsk - Head of Investor Relations Paul Hudson - Chief Executive Officer Francois Roger - Executive Vice President, Chief Financial Officer Houman Ashrafian - Executive Vice President, Head of Research and Development Thomas Triomphe - Executive Vice President, Vaccines Brian Foard - Executive Vice President, Head of Specialty Care Brendan O'Callaghan - Executive Vice President, Manufacturing and Supply Roy Papatheodorou - Executive Vice President, General Counsel Conference Call Participants Richard Vosser - JPMorgan Emily Field - Barclays Graham Parry - BofA Seamus Fernandez - Guggenheim Jo Walton - UBS Peter Welford - Jefferies Luisa Hector - Berenberg Thibault Boutherin - Morgan Stanley Simon Baker - Redburn Steve Scala - TD Cowen David Risinger - Leerink Richard Parkes - BNP Exane Rajesh Kumar - HSBC Eric Berrigaud - Stifel Florent Cespedes - Bernstein Thomas Kudsk Welcome to the Q3 2024 Conference Call for Investors and Analysts. As usual, you can find the slides on sanofi.com.
seekingalpha.com
- 3 weeks ago
8. Profile Summary
Sanofi SNY
COUNTRY
FR
INDUSTRY
Drug Manufacturers - General
MARKET CAP
$ 126 B
Dividend Yield
0.00%
Description
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Contact
54, Rue La BoEtie, Paris, 75008
https://www.sanofi.com
IPO Date
July 1, 2002
Employees
86088
Officers
Mr. Dante Beccaria
Global Compliance Officer & Vice President
Mr. Laurent Gilhodes
Principal Accounting Officer and Vice President of Corporate Accounting
Mr. Thomas Kudsk Larsen
Head of Investor Relations
Mr. François-Xavier Roger
Executive Vice President & Chief Financial Officer
Mr. Roy Papatheodorou
Executive Vice President & General Counsel
Mr. Josep Catlla
Head of Communications
Ms. Madeleine Roach
Executive Vice President & Head of Business Operations
Dr. Josephine Fubara
Chief Science Officer of Consumer Health Care
Mr. Pierre Chancel
Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing
Mr. Paul Hudson
Chief Executive Officer & Director